摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-fluoro-4-methyl-2-oxa-4-azabicyclo[4.4.0]deca-6,8,10-trien-5-one | 915771-24-3

中文名称
——
中文别名
——
英文名称
9-fluoro-4-methyl-2-oxa-4-azabicyclo[4.4.0]deca-6,8,10-trien-5-one
英文别名
9-fluoro-4-methyl-2-oxa-4-azabicyclo[4.4.0]deca-7,9,11-trien-5-one;7-fluoro-3-methyl-2,3-dihydro-4H-1,3-benzoxazin-4-one;7-fluoro-3-methyl-2H-1,3-benzoxazin-4-one
9-fluoro-4-methyl-2-oxa-4-azabicyclo[4.4.0]deca-6,8,10-trien-5-one化学式
CAS
915771-24-3
化学式
C9H8FNO2
mdl
——
分子量
181.166
InChiKey
HDGWFTVUCOOVNT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • CHEMICAL COMPOUNDS
    申请人:Campbell Leonie
    公开号:US20080171734A1
    公开(公告)日:2008-07-17
    The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R 1 , A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
    这项发明涉及一类新型化合物,其化学式为(I)或其盐:其中R1、A和HET-1如规范中所述,可能在通过葡萄糖激酶(GLK)介导的疾病或医疗状况的治疗或预防中有用,例如2型糖尿病。该发明还涉及包括所述化合物的药物组合物,使用所述化合物治疗由GLK介导的疾病的方法,以及制备化合物(I)的方法。
  • Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
    申请人:McKerrecher Darren
    公开号:US20090105214A1
    公开(公告)日:2009-04-23
    Compounds of formula (I), wherein R 1 , R 4 , HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
    式(I)的化合物中,其中R1、R4、HET-1和HET-2如规范所述,以及它们的盐和前药,是葡萄糖激酶(GLK)的激活剂,因此在治疗例如2型糖尿病方面是有用的。本文还描述了制备式(I)化合物的过程。
  • Chemical compounds
    申请人:AstraZeneca AB
    公开号:US07902200B2
    公开(公告)日:2011-03-08
    The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
    本发明涉及一种新的化合物组,其化学式为(I)或其盐:其中R1、A和HET-1如说明书所述,可用于治疗或预防通过葡萄糖激酶(GLK)介导的疾病或医疗状况,例如2型糖尿病。本发明还涉及包含上述化合物的制药组合物,使用上述化合物治疗由GLK介导的疾病的方法以及制备化合物(I)的方法。
  • HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
    申请人:AstraZeneca AB
    公开号:EP1891058A1
    公开(公告)日:2008-02-27
  • BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK
    申请人:Astra Zeneca AB
    公开号:EP2086964A2
    公开(公告)日:2009-08-12
查看更多